Medicare's GLP-1 Bridge Program: Coverage Explained
Correction: An earlier version of this article reproduced the NIDDK medication table with several cells cut short, including three "Do not take if you have" cells; the full conditions were restored on August 24, 2026, among them multiple endocrine neoplasia syndrome type 2 (MEN 2) for liraglutide, and the bupropion and alcohol-withdrawal conditions for naltrexone-bupropion. An earlier version also said that some compounders sell salt forms of semaglutide and that the FDA had identified fraudulent compounded products; the FDA's wording is that it is aware some products may be salt forms and aware of fraudulent ones, and those hedges were restored on August 5, 2026.
Medicare now covers certain GLP-1 weight-loss drugs. Not every drug, not every person — and not through the plan rules you already know. The coverage runs through a separate, temporary program with its own eligibility list and its own flat copay. Most of the substance lives in the fine print, so that’s where this article goes.
Starting July 1, 2026, Medicare covers certain GLP-1 drugs — Foundayo, Wegovy, and Zepbound in KwikPen form only — under the temporary Medicare GLP-1 Bridge program. It is open to people 18 or older with Medicare drug coverage who meet one of three BMI-based requirements. The copay is $50 a month, and a prescription plus prior authorization is required.
What the GLP-1 Bridge Program Is
The Medicare GLP-1 Bridge program is a temporary program that began on July 1, 2026. It is available nationwide, including all states and U.S. territories. Medicare describes the covered drugs plainly: they “can help you manage your weight and improve your health.”
The program is not part of your regular drug benefit. It runs alongside it — a distinction that sounds like bureaucratic trivia until the bill arrives.
To use it, you need Medicare drug coverage (Part D) in one of several forms: a standalone Medicare drug plan, a Medicare Advantage coordinated care plan with drug coverage (HMO, HMOPOS, or a Local or Regional PPO), a Special Needs Plan, an employer or union group waiver plan, or the Limited Income Newly Eligible Transition program. If that landscape of plan types is unfamiliar, Medicare’s four parts and enrollment windows are worth understanding first.
Who Qualifies, According to Medicare
You must be 18 or older, and you must meet one of three requirements at the time you start GLP-1 therapy. Each requirement pairs a body mass index threshold with a specific list of conditions. The lists do not mix.
Some background helps here. BMI is a measure of your weight in relation to your height; the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) defines a BMI between 25 and 30 as overweight and a BMI of 30 or greater as obesity.
Medicare’s three paths:
- A BMI of 35 or higher. No additional condition required.
- A BMI of 30 or higher, plus at least one of these: diastolic heart failure (also called heart failure with preserved ejection fraction), uncontrolled high blood pressure (hypertension), or chronic kidney disease at stage 3a or higher.
- A BMI of 27 or higher, plus at least one of these: prediabetes, a previous heart attack (myocardial infarction) or stroke, or blocked arteries in the legs or arms (peripheral artery disease) with symptoms.
There are exclusions, and they are precise. You are not eligible if you already get GLP-1 drugs covered through your Medicare Part D plan — though Medicare notes you can keep getting the drug through your current plan. You are also not eligible if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease; for those conditions, Medicare says your Part D plan might cover your GLP-1s. That “might” is Medicare’s word, not mine. The page leaves it conditional.
Which Drugs Are Covered — and How
The covered list is short and specific. Foundayo, a tablet. Wegovy, as an injection or a tablet. Zepbound, but only in KwikPen form — the program does not cover single-dose Zepbound vials or pens. That last restriction is easy to miss. It is also exactly the sort of detail that surprises people at a pharmacy counter.
Getting covered takes two steps on the provider side. Your doctor or other health care provider sends a prescription for a covered drug to the pharmacy, and when requested, completes a prior authorization. The provider must also certify that you’re using the drug as part of a lifestyle program focused on diet and exercise. Once covered, Medicare sends a letter in the mail confirming your drug is covered under Medicare GLP-1 Bridge.
At the pharmacy counter itself, Medicare says the pharmacy may ask for your Medicare Number or the last four digits of your Social Security Number to process the prescription. That request happens at the pharmacy, in the course of filling a prescription. Medicare’s page adds a fraud note of its own: if you suspect fraud, call 1-800-MEDICARE (1-800-633-4227). Phone calls asking for those same numbers out of the blue are covered in our guide to government impersonation phone scams.
NIDDK — which uses the term “weight management medications” — maintains a roster of prescription medications approved for long-term use. Its overview notes these medications work in different ways as a class: some may help you feel less hungry or full sooner, while others make it harder for the body to absorb fat from food.
Prescription medications approved for long-term use to treat overweight and obesity, per NIDDK (page last reviewed June 2024; the source does not state a year for the list itself). Conditions inside a cell are shown as bullets here; the source presents them as lists.
| Weight Management Medication | Approved For | How It Works | Do Not Take If You Have These Conditions |
|---|---|---|---|
| orlistat (Xenical) A pill taken by mouth 3 times per day Available in lower dose without prescription (Alli) | Adults and children ages 12 years and older | Works in your gut to reduce the amount of fat your body absorbs from the food you eat | Do not take if you have • problems absorbing nutrients from the food you eat • cholestasis |
| phentermine-topiramate (Qsymia) A pill taken by mouth once per day | Adults and children ages 12 years and older | • A mix of two medications: phentermine, which lessens your appetite, and topiramate, which is used to treat seizures or migraine headaches • May make you less hungry or feel full sooner |
Do not take if you have • glaucoma • hyperthyroidism • taken certain antidepressants called monoamine oxidase inhibitors (MAOIs) in the past 14 days |
| naltrexone-bupropion (Contrave) A pill taken by mouth 1 to 2 times per day | Adults | • A mix of two medications: naltrexone, which is used to treat alcohol and drug dependence, and bupropion, which is used to treat depression or help people quit smoking • May make you feel less hungry or full sooner |
Do not take if you have • uncontrolled high blood pressure • seizures • anorexia or bulimia nervosa • taken certain antidepressants called MAOIs in the past 14 days • frequent opioid use or are taking other medications containing bupropion, such as Wellbutrin or Zyban • abruptly stopped drinking alcohol or taking drugs, including ◦ benzodiazepines ◦ barbiturates ◦ antiepileptics |
| liraglutide (Saxenda) Given daily by injection | Adults and children ages 12 years and older | • Mimics a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake • At a lower dose under a different name, Victoza, this drug is FDA-approved to treat type 2 diabetes |
Do not take if you have • a personal or family history of a type of thyroid cancer called medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) |
| semaglutide (Wegovy) Given weekly by injection | Adults and children ages 12 years and older | • Mimics a hormone called GLP-1 that targets areas of the brain that regulate appetite and food intake • Under different names and dosages, this drug is FDA-approved to treat type 2 diabetes as an injectable medication (Ozempic) and as an oral pill (Rybelsus) |
Do not take if you have • a personal or family history of a type of thyroid cancer called MTC or MEN 2 |
| setmelanotide (IMCIVREE) Given daily by injection | • People ages 6 years and older with obesity due to one of four specific, rare, genetic conditions confirmed by genetic testing, including ◦ proopiomelanocortin (POMC) deficiency ◦ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency ◦ leptin receptor (LEPR) deficiency ◦ Bardet-Biedl syndrome (BBS) |
• Activates pathways in the brain to promote weight loss by decreasing appetite and food intake while increasing the number of calories the body uses | |
| tirzepatide (Zepbound) Given weekly by injection | Adults | • Mimics two hormones, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1, to target areas of the brain that regulate appetite and food intake • Under a different name, this drug is FDA-approved to treat type 2 diabetes as an injectable medication (Mounjaro) |
Do not take if you have • a personal or family history of a type of thyroid cancer called MTC or MEN 2 |
The $50 Monthly Copay and Its Limits
The price at the counter is a $50 copayment for a one-month supply — either 28 or 30 days, depending on the drug. Simple enough on its face. I had to read the list underneath it twice, because the list of things this copay does not do is longer than the list of things it does.
Because a separate Medicare program covers the drug rather than your regular drug coverage, the $50 does not count toward your yearly Medicare drug plan deductible or out-of-pocket limit. It won’t appear on your Part D Explanation of Benefits. It won’t appear on any Medicare Summary Notice either.
Two more limits deserve their own sentences. The copay cannot be lowered by programs like Extra Help, the Medicare program that helps people with limited income and resources pay Part D costs — the same program covered in our guide to Medicare cost-help programs. And it cannot be spread across multiple months using the Medicare Prescription Payment Plan. Fifty dollars, every month, standing entirely apart from the rest of your Medicare paperwork.
FDA-Approved vs. Compounded Semaglutide
Alongside the coverage question sits a separate one: what version of the drug is in the box. The FDA draws a careful line here, and the line matters, because “compounded” is not a synonym for “counterfeit” or “fraudulent.”
Compounded drugs occupy a legal but narrower lane. The FDA says a compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the approved drug is not commercially available. But compounded drugs are not FDA approved — the agency does not review them for safety, effectiveness, or quality before they are marketed.
Counterfeit drugs are a different thing entirely: products that claim to be authentic but could contain the wrong ingredients, too little or too much active ingredient, or none at all — and they are illegal. The FDA says separately that it is aware of fraudulent compounded semaglutide and tirzepatide carrying false information on the label, including cases where the pharmacy named on the label does not exist.
On compounded products specifically, the FDA has published two safety findings worth knowing. It has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide — errors that came from patients measuring incorrect doses themselves and, in some cases, from health professionals miscalculating them. It has also received complaints that certain compounded GLP-1 drugs arrived warm or with inadequate ice packs, which the agency says can affect the drug’s quality.
One more FDA detail. The agency says it is aware that some semaglutide products sold by compounders may be salt forms, such as semaglutide sodium and semaglutide acetate. Those salt forms, it says, are different active ingredients than the ones used in the approved drugs, and it is not aware of any lawful basis for their use in compounding.
What This Means If You’re on Medicare
The shape of this program is unusual, and the unusual parts are the ones to hold onto. Coverage exists, but through a track that runs beside your drug plan rather than inside it. The eligibility paths are exact — a BMI number paired with a fixed condition list — and the exclusions are just as exact. The drug list is three products, one of them restricted to a single pen format.
NIDDK’s overview adds useful realism about the medications themselves. It says weight management medications work best when combined with a lifestyle program, which matches Medicare’s requirement that a provider certify exactly that. It notes side effects vary by medication, are most often mild, and rarely can be serious — and that in the past, some weight management medications were removed from U.S. markets over health problems. It also says plainly that you will probably regain some weight after stopping the medication.
The program is temporary. Medicare’s page says so directly, and this article describes the program as it stands today.
Whether any of this fits a particular person’s health is a clinical question, and it belongs with a doctor or other qualified health professional who knows your conditions and your other medications. What Medicare has published is the map: who the program is for, which drugs it covers, and exactly what the $50 buys. The map is narrower than the headlines suggest, and knowing its edges is most of what a careful reader needs.
This article is general information, not professional advice. For decisions about your money or health, consult a qualified professional.